Beijing Mabworks Biotech Co., Ltd.

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
4Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
CD20Monoclonal antibody
Systemic Lupus ErythematosusFollicular LymphomaPrimary Membranous Nephropathy
Phase 1/2
GPRC5D x BCMA x CD3
Multiple Myeloma

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
MBS314Phase 1/2Multiple Myeloma
Est. primary completion 2027-12 · NCT07911748 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
Obinutuzumab beta (Bejescin)Phase 3Systemic Lupus Erythematosus
Est. primary completion 2028-12 · NCT07405970 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

4 June 2026Priority reviewObinutuzumab beta (Bejescin)NMPA marketing application for obinutuzumab beta (Bejescin) in primary membranous nephropathy under priority review (reported 2026-06-04)
CN, NMPA · Beijing Mabworks Biotech · Source ↗

Financial reports

No financial reports recorded.